Divi's Laboratories announced a robust financial performance for the March quarter of FY25, with a 25.6% YoY surge in standalone net profit, reaching Rs 667 crore. Revenue from operations also climbed by 12.26% to Rs 2,536 crore. The company's board declared a dividend of Rs 30 per share and (...)
Site référencé: The Economic Times
The Economic Times
Market caution justified after sharp rally, investors should stay vigilant : Sudip Bandyopadhyay
21/05/2025
Short-term dips seen as healthy realignments, not trend reversals : Deven Choksey
21/05/2025
Fund Manager Talk | Discretionary consumption sector set to outpace staples : Mirae’s Siddhant Chhabria
21/05/2025
Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
21/05/2025
Borana Weaves IPO Day 2 : After strong investor response, GMP soars to 28%. Check subscription
21/05/2025
What makes Balanced Advantage Funds a superior choice for investors ?
21/05/2025
